*Chicago Illinois*
4711 Golf Road
Suite 900
Skokie, IL 60076

ThrIVewell INFUSION
Office: 212-803-3339 Fax : 646-768-8600

REJUVEINATE

# Ublituximab-xiiy (Briumvi)

## Provider Order Form

**Date:** _____

## PATIENT INFORMATION

| | | |
|---|---|---|
| Name: | DOB: | SEX: M ☐ F ☐ |
| ICD-10 code (required): | ICD-10 description: | |
| ☐NKDA Allergies: | | Weight lbs/kg: |

## REFERRAL STATUS

☐New Referral ☐Referral Renewal ☐Medication/Order Change ☐Benefits Verification Only ☐Discontinuation Order

## PHYSICIAN INFORMATION

| | | |
|---|---|---|
| Referral Coordinator Name: | Referral Coordinator Email: | |
| Ordering Provider: | Provider NPI: | |
| Referring Practice Name: | Phone: | Fax: |
| Practice Address: | City: State: | Zip Code: |

### NURSING

☑ Hepatitis B status & date (list results here & attach clinicals)
_____

☑ Provide nursing care per ThrIVewell Procedures, including reaction management and post-procedure observation

***Based on the manufacturer PI, most payors require a quantitative serum immunoglobulin screening prior to Briumvi induction.***

☐ Ihave attached results from a recent quantitative serum immunoglobulin test (list results here & attach clinicals):
_____

☐ Iinstruct ThrIVewell to draw quantitative serum immunoglobulin prior to first induction infusion (if required by payor).

### LABORATORY ORDERS

☐ CBC ☐at each dose ☐ every _____
☐ CMP ☐at each dose ☐ every _____
☐ CRP ☐at each dose ☐ every _____
☐ Other:_____
Dose: _____ Route_____
Frequency:_____

### PRE-MEDICATION ORDERS

*The following are manufacturer recommended premedication regimens:*

☐ acetaminophen (Tylenol) ☐500mg / ☐650mg / ☐1000mg PO
☐ methylprednisolone (Solu-Medrol) ☐40mg / ☐125mg IV
☐ diphenhydramine (Benadryl) ☐25mg / ☐50mg ☐PO / IV

### ADDITIONAL PRE-MEDICATION ORDERS

☐ cetirizine (Zyrtec) 10mg PO
☐ loratadine (Claritin) 10mg PO
☐ Other: _____
Dose: _____ Route: _____
Frequency:_____

### THERAPY ADMINISTRATION

☑ **Ublituximab-xiiy (Briumvi) intravenous infusion**
☐ **Induction:**
**Dose: 150mg in 250ml 0.9% NS over four hours followed by 450mg in 250ml 0.9% NS over one hour two weeks later.**
**After induction, continue with the maintenance dosing and schedule below.**

☐ **Maintenance:**
**Dose: 450mg in 250ml 0.9%NS over one hour 24 weeks after the first infusion and every 24 weeks thereafter.**

☑ Flush with 0.9% NS at the completion of infusion
☑ Patient required to stay for 60 minute observation post infusion of first two infusions. If no infusion reaction or hypersensitivity has been observed, patient is not required to stay for subsequent infusions.

☐ Refills: ☐ Zero / ☐ for 12 months / ☐ _____
(if not indicated order will expire one year from date signed)

### SPECIAL INSTRUCTIONS

## ORDERING PROVIDER

Signature **X** _____ Date _____

Provider _____ Phone_____ Fax _____